Reengineered Peptides Modulating Toll-like Receptors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods face challenges in precisely modulating Toll-like receptors (TLRs) due to the complexity of the human microbiome and limitations in sample processing and data analysis, making it difficult to identify effective modulators for TLR-related conditions such as diabetes, obesity, and immune disorders.
Innovation Solution
Development of therapeutic compositions comprising peptides derived from reengineered peptide sequences associated with microorganism-related modulators of TLRs, which can bind to TLRs to modulate their functionality, including activators or inhibitors, and are designed to improve metabolic and immune-related conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current sample processing and data analysis methods are used to identify TLR modulators, then the process can be performed with existing technology, but the precision and effectiveness of identifying modulators is limited due to microbiome complexity
Solution Approach 1:
The patent segments the complex microbiome analysis problem into targeted identification of specific peptide sequences from microorganisms that modulate TLRs. Instead of analyzing the entire microbiome complexity, the invention focuses on identifying and characterizing specific modulator peptides, thereby improving precision while managing complexity through selective analysis
Solution Approach 2:
The invention changes the analytical parameters from general microbiome characterization to specific peptide sequence identification and binding affinity measurement. By shifting focus to quantifiable parameters such as peptide sequences and their binding characteristics to TLRs, the method achieves higher precision in modulator identification
2Adaptability or versatility
If a broad range of microbial ligands are used to target TLRs, then the coverage of TLR-related conditions can be improved, but the difficulty of identifying effective modulators increases
Solution Approach 1:
The patent creates simplified models and assays to detect and measure TLR modulator activity. By developing in vitro assays and computational models that replicate TLR-ligand interactions, the invention makes it easier to identify effective modulators across different TLR-related conditions without directly confronting the full complexity of in vivo microbial diversity
Solution Approach 2:
The invention develops a universal platform for identifying TLR modulators that can be applied across multiple TLR types and related conditions. The methodology creates a multi-functional approach that can screen for modulators of different TLRs (TLR2, TLR4, etc.) and apply to various conditions including metabolic and immune disorders, thereby improving versatility while standardizing the detection process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These peptides demonstrate improved binding affinity and specificity to TLRs, potentially offering a precise diagnostic and therapeutic approach for TLR-related conditions by modulating immune responses and interacting with microorganisms to treat metabolic and immune disorders.
Implementation Method 1
These peptides demonstrate improved binding affinity and specificity to TLRs
Data Source
AI summary
Therapeutic compositions and an associated method for improving a Toll-like receptor (TLR)-related condition, including determining a set of peptide sequences associated with a microorganism-related modulator of a TLR, determining a first set of binding parameters for the set of peptide sequences in relation to the TLR, selecting a target subset of peptide sequences from the set of peptide sequences based on the first set of binding parameters, reengineering the target subset of peptide sequences based on mutating amino acid residues of the target subset of peptide sequences, determining a second set of binding parameters for the reengineered target subset of peptide sequences in relation to the TLR, and identifying a first peptide for use in a therapeutic composition for improving the TLR-related condition, based on the second set of binding parameters for the reengineered target subset of peptide sequences.